The Baden-Württemberg healthcare industry - a recession-proof employer that has strong ties with the region - is of key importance for the state. It comprises the biotechnology and medical technology sectors and the pharmaceutical industry. In 2013, the industry with over 82,000 employees generated revenues of almost 23 billion euros.
Of all the German federal states, Baden-Württemberg has the largest number of pharmaceutical and medical technology companies and the second largest number of biotechnology companies. The healthcare industry in Baden-Württemberg is characterised by small- and medium-sized companies and is also home to global companies such as Roche, Boehringer Ingelheim, Aesculap and KARL STORZ.
Due to the presence of the entire value chain from research and development through to production and sales, the Baden-Württemberg healthcare industry benefits from optimal location factors. In addition, it is embedded into a dense network of (university) hospitals and research institutions.
All three sectors have above-average R&D expenditures (the pharmaceutical industry spends 13.2 percent, medical technology companies spend 9 percent, biotechnology companies spend 31.5 percent of their revenues on R&D), which reflect the companies' huge innovative power.
These figures were collected by BIOPRO and the Baden-Württemberg Statistics Office in 2015 for use in BIOPRO's latest Healthcare Industry report. The original report and the updated version can be downloaded from BIOPRO's webpage "Selected publications".